Autolus Therapeutics (Autolus Therapeutics) Float Percentage Of Total Shares Outstanding : 74.06% (As of May. 27, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Autolus Therapeutics's float shares is 197.02 Mil. Autolus Therapeutics's total shares outstanding is 266.04 Mil. Autolus Therapeutics's float percentage of total shares outstanding is 74.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Autolus Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Autolus Therapeutics's Institutional Ownership is 13.57%.

Autolus Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Autolus Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	197.02	/	266.04
	=	74.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.